ES2629690T3 - Inhibidores de aminopirimidina quinasa - Google Patents
Inhibidores de aminopirimidina quinasa Download PDFInfo
- Publication number
- ES2629690T3 ES2629690T3 ES12780393.0T ES12780393T ES2629690T3 ES 2629690 T3 ES2629690 T3 ES 2629690T3 ES 12780393 T ES12780393 T ES 12780393T ES 2629690 T3 ES2629690 T3 ES 2629690T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- aryl
- heteroatoms
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 4
- 150000005005 aminopyrimidines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 227
- 125000003118 aryl group Chemical group 0.000 claims abstract description 128
- 125000001424 substituent group Chemical group 0.000 claims abstract description 115
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 107
- -1 1,4-cyclohexanediyl Chemical group 0.000 claims abstract description 106
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 84
- 150000004820 halides Chemical class 0.000 claims abstract description 78
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 69
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 43
- 125000005879 dioxolanyl group Chemical group 0.000 claims abstract description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 42
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 27
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 26
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 24
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims abstract description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 125000006237 oxymethylenoxy group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 9
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 157
- 125000004076 pyridyl group Chemical group 0.000 claims description 53
- 125000002541 furyl group Chemical group 0.000 claims description 47
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 102000008122 Casein Kinase I Human genes 0.000 claims description 39
- 108010049812 Casein Kinase I Proteins 0.000 claims description 39
- 125000001544 thienyl group Chemical group 0.000 claims description 39
- 125000002883 imidazolyl group Chemical group 0.000 claims description 35
- 125000000335 thiazolyl group Chemical group 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 34
- 210000001519 tissue Anatomy 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 30
- 102000052052 Casein Kinase II Human genes 0.000 claims description 28
- 108010010919 Casein Kinase II Proteins 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 21
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 16
- SMBZJSVIKJMSFP-UHFFFAOYSA-N trifluoromethyl hypofluorite Chemical compound FOC(F)(F)F SMBZJSVIKJMSFP-UHFFFAOYSA-N 0.000 claims description 15
- 210000000988 bone and bone Anatomy 0.000 claims description 13
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
- 102100037397 Casein kinase I isoform gamma-1 Human genes 0.000 claims description 11
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 11
- 101001026384 Homo sapiens Casein kinase I isoform gamma-1 Proteins 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 230000001594 aberrant effect Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 150000002222 fluorine compounds Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000013016 Hypoglycemia Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 210000000133 brain stem Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000013020 embryo development Effects 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 210000000436 anus Anatomy 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 239000004305 biphenyl Chemical group 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 210000000777 hematopoietic system Anatomy 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 210000005228 liver tissue Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 3
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 3
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 210000004994 reproductive system Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 230000002381 testicular Effects 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 97
- 238000006268 reductive amination reaction Methods 0.000 description 82
- 239000000203 mixture Substances 0.000 description 49
- 125000003545 alkoxy group Chemical group 0.000 description 48
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 48
- 230000037361 pathway Effects 0.000 description 45
- 230000001225 therapeutic effect Effects 0.000 description 36
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000003814 drug Substances 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 22
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 22
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 21
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 21
- 239000001257 hydrogen Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 102000013814 Wnt Human genes 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 13
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 13
- 101001001645 Homo sapiens Serine/threonine-protein kinase pim-3 Proteins 0.000 description 13
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 13
- 102100036119 Serine/threonine-protein kinase pim-3 Human genes 0.000 description 13
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 13
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 108091007924 CK1γ Proteins 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 108091008611 Protein Kinase B Proteins 0.000 description 10
- 239000002253 acid Chemical group 0.000 description 10
- 150000001299 aldehydes Chemical group 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 9
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 238000006073 displacement reaction Methods 0.000 description 9
- 150000002148 esters Chemical group 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 8
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 8
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- SKPLQVOMAMUUJD-XQRVVYSFSA-N (5z)-5-[(2-methylsulfonylpyrimidin-4-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CS(=O)(=O)C1=NC=CC(\C=C/2C(NC(=O)S\2)=O)=N1 SKPLQVOMAMUUJD-XQRVVYSFSA-N 0.000 description 7
- QGJXHPACBLAFFJ-UHFFFAOYSA-N 2-methylsulfanylpyrimidine-4-carbaldehyde Chemical compound CSC1=NC=CC(C=O)=N1 QGJXHPACBLAFFJ-UHFFFAOYSA-N 0.000 description 7
- PTYFBMBIEDVSIA-UHFFFAOYSA-N 4-(dimethoxymethyl)-2-methylsulfanylpyrimidine Chemical compound COC(OC)C1=CC=NC(SC)=N1 PTYFBMBIEDVSIA-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000032612 Glial tumor Diseases 0.000 description 7
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 108010083755 proto-oncogene proteins pim Proteins 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- YOPCRCAWBXXHIH-XQRVVYSFSA-N (5z)-5-[(2-methylsulfanylpyrimidin-4-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CSC1=NC=CC(\C=C/2C(NC(=O)S\2)=O)=N1 YOPCRCAWBXXHIH-XQRVVYSFSA-N 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000013316 polymer of intrinsic microporosity Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 201000000849 skin cancer Diseases 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- 150000003456 sulfonamides Chemical class 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- UPRCKKVQTPHFKG-UHFFFAOYSA-N 6-thiophen-3-ylpyridine-2-carbaldehyde Chemical compound O=CC1=CC=CC(C2=CSC=C2)=N1 UPRCKKVQTPHFKG-UHFFFAOYSA-N 0.000 description 5
- 206010003571 Astrocytoma Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 5
- ABKLAEGOCPBSOU-UHFFFAOYSA-M sodium;4-(dimethoxymethyl)pyrimidine-2-thiolate Chemical compound [Na+].COC(OC)C1=CC=NC([S-])=N1 ABKLAEGOCPBSOU-UHFFFAOYSA-M 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- PEKGMKQAZDWJQM-HYXAFXHYSA-N (5z)-5-[(2-aminopyrimidin-4-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound NC1=NC=CC(\C=C/2C(NC(=O)S\2)=O)=N1 PEKGMKQAZDWJQM-HYXAFXHYSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 208000021309 Germ cell tumor Diseases 0.000 description 4
- KBHCPIJKJQNHPN-UHFFFAOYSA-N N=NP(O)=O Chemical group N=NP(O)=O KBHCPIJKJQNHPN-UHFFFAOYSA-N 0.000 description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 208000009359 Sezary Syndrome Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000009615 deamination Effects 0.000 description 4
- 238000006481 deamination reaction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002267 hypothalamic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 208000027747 Kennedy disease Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000024386 fungal infectious disease Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 3
- RZKXBGFREHUUOD-UHFFFAOYSA-N 1-(6-thiophen-3-ylpyridin-2-yl)ethanone Chemical compound CC(=O)C1=CC=CC(C2=CSC=C2)=N1 RZKXBGFREHUUOD-UHFFFAOYSA-N 0.000 description 2
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 2
- NZNFCDOWRMQIDH-UHFFFAOYSA-N 2-methylquinoline-4-carbaldehyde Chemical compound C1=CC=CC2=NC(C)=CC(C=O)=C21 NZNFCDOWRMQIDH-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- FJDBLPHTECJIFI-UHFFFAOYSA-N 4-fluoro-2-(furan-2-yl)benzaldehyde Chemical compound FC1=CC=C(C=O)C(C=2OC=CC=2)=C1 FJDBLPHTECJIFI-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 description 2
- 102000007368 Ataxin-7 Human genes 0.000 description 2
- 108010032953 Ataxin-7 Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 101000915806 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Proteins 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- VYEAHXRPWKOEMY-UHFFFAOYSA-N O-(9H-fluoren-9-ylmethyl)hydroxylamine Chemical compound C1=CC=C2C(CON)C3=CC=CC=C3C2=C1 VYEAHXRPWKOEMY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- BHVRCUAHXVLSNX-UHFFFAOYSA-N O-[(4,5-dimethoxy-2-nitrophenyl)methyl]hydroxylamine Chemical compound COC1=CC(CON)=C([N+]([O-])=O)C=C1OC BHVRCUAHXVLSNX-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical group S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 2
- GYCAHBIKRFTGPJ-INSMAYOISA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C2=CSC=C2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C2=CSC=C2)=N1 GYCAHBIKRFTGPJ-INSMAYOISA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 102100029014 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Human genes 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 150000001540 azides Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- LUFPJJNWMYZRQE-UHFFFAOYSA-N benzylsulfanylmethylbenzene Chemical compound C=1C=CC=CC=1CSCC1=CC=CC=C1 LUFPJJNWMYZRQE-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
- 208000030239 cerebral astrocytoma Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 238000004460 liquid liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030883 malignant astrocytoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000005151 nonafluorobutanesulfonyl group Chemical group FC(C(C(S(=O)(=O)*)(F)F)(F)F)(C(F)(F)F)F 0.000 description 2
- LUHFJLLCZSYACL-UHFFFAOYSA-N o-(2,2,2-trichloroethyl)hydroxylamine Chemical compound NOCC(Cl)(Cl)Cl LUHFJLLCZSYACL-UHFFFAOYSA-N 0.000 description 2
- GWCBVFMHGHMALR-UHFFFAOYSA-N o-(2-trimethylsilylethyl)hydroxylamine Chemical compound C[Si](C)(C)CCON GWCBVFMHGHMALR-UHFFFAOYSA-N 0.000 description 2
- HFMYNBFAXIDOIO-UHFFFAOYSA-N o-[2-(benzenesulfonyl)ethyl]hydroxylamine Chemical compound NOCCS(=O)(=O)C1=CC=CC=C1 HFMYNBFAXIDOIO-UHFFFAOYSA-N 0.000 description 2
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 2
- KKVUFSINQFSJNK-UHFFFAOYSA-N o-tert-butylhydroxylamine Chemical compound CC(C)(C)ON KKVUFSINQFSJNK-UHFFFAOYSA-N 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000000239 visual pathway Anatomy 0.000 description 2
- 230000004400 visual pathway Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIGNCHWLGQKOIP-FLIBITNWSA-N (5z)-5-[(2-anilinopyrimidin-4-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(NC=2C=CC=CC=2)=N1 IIGNCHWLGQKOIP-FLIBITNWSA-N 0.000 description 1
- GULPGWOSWCPGTE-WQLSENKSSA-N (5z)-5-[[2-(3-methoxyanilino)pyrimidin-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound COC1=CC=CC(NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 GULPGWOSWCPGTE-WQLSENKSSA-N 0.000 description 1
- MNGXDHSFITXPNH-YVLHZVERSA-N (5z)-5-[[2-[[1-(pyridin-3-ylmethyl)piperidin-4-yl]methylamino]pyrimidin-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(NCC2CCN(CC=3C=NC=CC=3)CC2)=N1 MNGXDHSFITXPNH-YVLHZVERSA-N 0.000 description 1
- RDPHFFIZFJBXOK-MTJSOVHGSA-N (5z)-5-[[2-[[1-[(6-thiophen-3-ylpyridin-2-yl)methyl]piperidin-4-yl]methylamino]pyrimidin-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(NCC2CCN(CC=3N=C(C=CC=3)C3=CSC=C3)CC2)=N1 RDPHFFIZFJBXOK-MTJSOVHGSA-N 0.000 description 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 1
- 125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
- 125000005845 (C2-C12)alkanoyloxymethyl group Chemical group 0.000 description 1
- ULVSHNOGEVXRDR-UHFFFAOYSA-N 1,1-dimethoxypropan-2-one Chemical compound COC(OC)C(C)=O ULVSHNOGEVXRDR-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000005860 1-((C1-C6)alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- LLLBDLDNTMMZHL-UHFFFAOYSA-N 1-benzofuran-5-carbaldehyde Chemical compound O=CC1=CC=C2OC=CC2=C1 LLLBDLDNTMMZHL-UHFFFAOYSA-N 0.000 description 1
- YPWUQMKWNNQMDX-UHFFFAOYSA-N 1-fluoronaphthalene-2-carbaldehyde Chemical compound C1=CC=C2C(F)=C(C=O)C=CC2=C1 YPWUQMKWNNQMDX-UHFFFAOYSA-N 0.000 description 1
- 125000005847 1-methyl-1-(alkanoyloxy)-ethyl group Chemical group 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HRJOIUQTUKHOMQ-UHFFFAOYSA-N 1h-indole;7h-purine Chemical compound C1=CC=C2NC=CC2=C1.C1=NC=C2NC=NC2=N1 HRJOIUQTUKHOMQ-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- PRGXFOVLCYTXLB-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1C1=CC=NN1 PRGXFOVLCYTXLB-UHFFFAOYSA-N 0.000 description 1
- PDWKLAWWUSFIMF-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1C1=CC=CN1 PDWKLAWWUSFIMF-UHFFFAOYSA-N 0.000 description 1
- BHCQHUHAUPAYCW-UHFFFAOYSA-N 2-(2,2,2-trifluoroethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)(F)COC1=NC=CC=C1C=O BHCQHUHAUPAYCW-UHFFFAOYSA-N 0.000 description 1
- ZYNNXRUYVVQLOW-UHFFFAOYSA-N 2-(2-methoxyphenyl)benzaldehyde Chemical compound COC1=CC=CC=C1C1=CC=CC=C1C=O ZYNNXRUYVVQLOW-UHFFFAOYSA-N 0.000 description 1
- KCXZRESSSSYYCW-UHFFFAOYSA-N 2-(4-fluorophenyl)acetaldehyde Chemical compound FC1=CC=C(CC=O)C=C1 KCXZRESSSSYYCW-UHFFFAOYSA-N 0.000 description 1
- QENDTDXVOJYDLG-UHFFFAOYSA-N 2-(4-fluorophenyl)benzaldehyde Chemical compound C1=CC(F)=CC=C1C1=CC=CC=C1C=O QENDTDXVOJYDLG-UHFFFAOYSA-N 0.000 description 1
- BJGHSPJMFHHOCJ-UHFFFAOYSA-N 2-(furan-2-yl)benzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CO1 BJGHSPJMFHHOCJ-UHFFFAOYSA-N 0.000 description 1
- SYHHRFRBVDJKFJ-UHFFFAOYSA-N 2-(furan-2-yl)pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1C1=CC=CO1 SYHHRFRBVDJKFJ-UHFFFAOYSA-N 0.000 description 1
- NEWRSHVOGXHTJA-UHFFFAOYSA-N 2-(furan-3-yl)benzaldehyde Chemical compound O=CC1=CC=CC=C1C1=COC=C1 NEWRSHVOGXHTJA-UHFFFAOYSA-N 0.000 description 1
- OVOIXXFZGUYOQQ-UHFFFAOYSA-N 2-(furan-3-yl)pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1C1=COC=C1 OVOIXXFZGUYOQQ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- PHTNYSHNYFGRRK-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C1=NC=CC=C1C=O PHTNYSHNYFGRRK-UHFFFAOYSA-N 0.000 description 1
- GZFJLFFCCRITHH-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]acetaldehyde Chemical compound FC1=C(CC=O)C=CC=C1C(F)(F)F GZFJLFFCCRITHH-UHFFFAOYSA-N 0.000 description 1
- QALJGJYPRCMIAW-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenyl]pyridine-3-carbaldehyde Chemical compound FC(F)(F)OC1=CC=CC(C=2C(=CC=CN=2)C=O)=C1 QALJGJYPRCMIAW-UHFFFAOYSA-N 0.000 description 1
- WAIZVXFWKGPJGT-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=2C(=CC=CN=2)C=O)=C1 WAIZVXFWKGPJGT-UHFFFAOYSA-N 0.000 description 1
- UUSBTGUDEHRZTF-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]benzaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1C=O UUSBTGUDEHRZTF-UHFFFAOYSA-N 0.000 description 1
- ZLEQEXDQUVKWKY-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]pyridine-3-carbaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC=CC=C1C=O ZLEQEXDQUVKWKY-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- OFBVGDCXXGXDKU-UHFFFAOYSA-N 2-fluoropyridine-3-carbaldehyde Chemical compound FC1=NC=CC=C1C=O OFBVGDCXXGXDKU-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- PIFFMIDNNWOQLK-UHFFFAOYSA-N 2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=CC=C1C=O PIFFMIDNNWOQLK-UHFFFAOYSA-N 0.000 description 1
- JHRPHASLIZOEBJ-UHFFFAOYSA-N 2-methylpyridine-3-carbaldehyde Chemical compound CC1=NC=CC=C1C=O JHRPHASLIZOEBJ-UHFFFAOYSA-N 0.000 description 1
- BPBDVCVMDGMPEW-UHFFFAOYSA-N 2-pyridin-2-ylacetaldehyde Chemical compound O=CCC1=CC=CC=N1 BPBDVCVMDGMPEW-UHFFFAOYSA-N 0.000 description 1
- DTUANRRVVJRTJS-UHFFFAOYSA-N 2-pyridin-3-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CN=C1 DTUANRRVVJRTJS-UHFFFAOYSA-N 0.000 description 1
- HPSCYFZOYJSYGZ-UHFFFAOYSA-N 2-pyridin-4-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=NC=C1 HPSCYFZOYJSYGZ-UHFFFAOYSA-N 0.000 description 1
- HAUWSNYPEZPXNX-UHFFFAOYSA-N 2-thiophen-3-ylpyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1C1=CSC=C1 HAUWSNYPEZPXNX-UHFFFAOYSA-N 0.000 description 1
- 238000012573 2D experiment Methods 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- IVYDCJYMOBKHTK-UHFFFAOYSA-N 3-(4-fluorophenyl)benzaldehyde Chemical compound C1=CC(F)=CC=C1C1=CC=CC(C=O)=C1 IVYDCJYMOBKHTK-UHFFFAOYSA-N 0.000 description 1
- BTAANNDAXIYWAN-UHFFFAOYSA-N 3-(furan-2-yl)benzaldehyde Chemical compound O=CC1=CC=CC(C=2OC=CC=2)=C1 BTAANNDAXIYWAN-UHFFFAOYSA-N 0.000 description 1
- FIIIEUQXYKDPRD-UHFFFAOYSA-N 3-(trifluoromethyl)pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=CN=C1C=O FIIIEUQXYKDPRD-UHFFFAOYSA-N 0.000 description 1
- FUQDVSPEJKKYQH-UHFFFAOYSA-N 3-[2-(trifluoromethyl)phenyl]benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=CC(C=O)=C1 FUQDVSPEJKKYQH-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- NTHCVKPOWDMRGY-UHFFFAOYSA-N 3-thiophen-2-ylbenzaldehyde Chemical compound O=CC1=CC=CC(C=2SC=CC=2)=C1 NTHCVKPOWDMRGY-UHFFFAOYSA-N 0.000 description 1
- HOQKGZHXQLZFBT-UHFFFAOYSA-N 3-thiophen-3-ylbenzaldehyde Chemical compound O=CC1=CC=CC(C2=CSC=C2)=C1 HOQKGZHXQLZFBT-UHFFFAOYSA-N 0.000 description 1
- CAHPDCGTTHGHLA-UHFFFAOYSA-N 4-(furan-3-yl)pyridine-3-carbaldehyde Chemical compound O=CC1=CN=CC=C1C1=COC=C1 CAHPDCGTTHGHLA-UHFFFAOYSA-N 0.000 description 1
- DYRMBQRXOMOMNW-UHFFFAOYSA-N 4-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=NC=C1C=O DYRMBQRXOMOMNW-UHFFFAOYSA-N 0.000 description 1
- QYGIKDWXTMCEEW-UHFFFAOYSA-N 4-fluoro-2-(furan-3-yl)benzaldehyde Chemical compound FC1=CC=C(C=O)C(C2=COC=C2)=C1 QYGIKDWXTMCEEW-UHFFFAOYSA-N 0.000 description 1
- HPIMKRCDFOQWLK-UHFFFAOYSA-N 4-fluoro-2-phenylbenzaldehyde Chemical compound FC1=CC=C(C=O)C(C=2C=CC=CC=2)=C1 HPIMKRCDFOQWLK-UHFFFAOYSA-N 0.000 description 1
- CVMGZMLRVQLWNU-UHFFFAOYSA-N 4-fluoro-2-pyridin-3-ylbenzaldehyde Chemical compound FC1=CC=C(C=O)C(C=2C=NC=CC=2)=C1 CVMGZMLRVQLWNU-UHFFFAOYSA-N 0.000 description 1
- LMCPPKJNVHGJGH-UHFFFAOYSA-N 4-fluoro-2-thiophen-2-ylbenzaldehyde Chemical compound FC1=CC=C(C=O)C(C=2SC=CC=2)=C1 LMCPPKJNVHGJGH-UHFFFAOYSA-N 0.000 description 1
- NUCQZGWGWFEPFN-UHFFFAOYSA-N 4-fluoro-2-thiophen-3-ylbenzaldehyde Chemical compound FC1=CC=C(C=O)C(C2=CSC=C2)=C1 NUCQZGWGWFEPFN-UHFFFAOYSA-N 0.000 description 1
- QWUFIMUCFQUBOT-UHFFFAOYSA-N 4-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=NC=C1C=O QWUFIMUCFQUBOT-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- XGGHEBGOZWCTKF-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carbonyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)N=C1 XGGHEBGOZWCTKF-UHFFFAOYSA-N 0.000 description 1
- YAGPZRLCMRMSFP-UHFFFAOYSA-N 5-fluoro-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(F)C=C1C=O YAGPZRLCMRMSFP-UHFFFAOYSA-N 0.000 description 1
- NGPNULCLKRZORF-UHFFFAOYSA-N 6-(furan-2-yl)pyridine-2-carbaldehyde Chemical compound O=CC1=CC=CC(C=2OC=CC=2)=N1 NGPNULCLKRZORF-UHFFFAOYSA-N 0.000 description 1
- FIUUSAJAVPIISC-UHFFFAOYSA-N 6-(furan-3-yl)pyridine-2-carbaldehyde Chemical compound O=CC1=CC=CC(C2=COC=C2)=N1 FIUUSAJAVPIISC-UHFFFAOYSA-N 0.000 description 1
- UQGRBLVDXGXUEM-UHFFFAOYSA-N 6-[2-(trifluoromethyl)phenyl]pyridine-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=CC(C=O)=N1 UQGRBLVDXGXUEM-UHFFFAOYSA-N 0.000 description 1
- IAZWESCHJCWOSL-UHFFFAOYSA-N 6-fluoronaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(F)=CC=C21 IAZWESCHJCWOSL-UHFFFAOYSA-N 0.000 description 1
- HENWRHPVXMPQNF-UHFFFAOYSA-N 6-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=CC(C=O)=N1 HENWRHPVXMPQNF-UHFFFAOYSA-N 0.000 description 1
- JDQMJKKGPXPPOJ-UHFFFAOYSA-N 6-fluoroquinoline-2-carbaldehyde Chemical compound N1=C(C=O)C=CC2=CC(F)=CC=C21 JDQMJKKGPXPPOJ-UHFFFAOYSA-N 0.000 description 1
- AHISYUZBWDSPQL-UHFFFAOYSA-N 6-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=CC(C=O)=N1 AHISYUZBWDSPQL-UHFFFAOYSA-N 0.000 description 1
- NRSDBRGRLFTCSW-UHFFFAOYSA-N 6-oxo-1h-pyridazine-3-carbaldehyde Chemical compound OC1=CC=C(C=O)N=N1 NRSDBRGRLFTCSW-UHFFFAOYSA-N 0.000 description 1
- HZFJKPQZABOKLA-UHFFFAOYSA-N 6-thiophen-2-ylpyridine-2-carbaldehyde Chemical compound O=CC1=CC=CC(C=2SC=CC=2)=N1 HZFJKPQZABOKLA-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- SDTPRCBMOHXTEG-YASBIWDDSA-N C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 SDTPRCBMOHXTEG-YASBIWDDSA-N 0.000 description 1
- LNCHTMXUANMYRU-KXVRCEMPSA-N C1=CC(C(F)(F)F)=CC=C1C1=NC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 LNCHTMXUANMYRU-KXVRCEMPSA-N 0.000 description 1
- BFZWNORFFXRNFK-APOOPQLTSA-N C1=CC(F)=CC=C1C1=CC=CC(CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 Chemical compound C1=CC(F)=CC=C1C1=CC=CC(CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 BFZWNORFFXRNFK-APOOPQLTSA-N 0.000 description 1
- MXRHEBFKNBTFKW-YASBIWDDSA-N C1=CC(F)=CC=C1C1=CC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound C1=CC(F)=CC=C1C1=CC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 MXRHEBFKNBTFKW-YASBIWDDSA-N 0.000 description 1
- WSEYCAFAKGJNFV-VXDSSLBNSA-N C1=CC=C(C(F)(F)F)C(F)=C1CCN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1CCN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 WSEYCAFAKGJNFV-VXDSSLBNSA-N 0.000 description 1
- ADGQGLFNGYZYIL-JPBSBIHGSA-N CC1=NC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound CC1=NC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 ADGQGLFNGYZYIL-JPBSBIHGSA-N 0.000 description 1
- AEPWIWVKLBRGEB-JOWHBADWSA-N COC1=CC=CC=C1C1=CC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound COC1=CC=CC=C1C1=CC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 AEPWIWVKLBRGEB-JOWHBADWSA-N 0.000 description 1
- 101150047910 CSNK1D gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- GWTDVRCSKBRETF-KXVRCEMPSA-N FC(F)(F)C1=CC=CC(C=2C(=CC=CN=2)CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 Chemical compound FC(F)(F)C1=CC=CC(C=2C(=CC=CN=2)CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 GWTDVRCSKBRETF-KXVRCEMPSA-N 0.000 description 1
- HRMLWAKYUNWXRZ-JKEUBQDTSA-N FC(F)(F)C1=CC=CC=C1C1=CC=CC(CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=CC(CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 HRMLWAKYUNWXRZ-JKEUBQDTSA-N 0.000 description 1
- LKQJLGDPHDEQPU-QPFUBSCQSA-N FC(F)(F)C1=CC=CC=C1C1=CC=CC(CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=N1 Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=CC(CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=N1 LKQJLGDPHDEQPU-QPFUBSCQSA-N 0.000 description 1
- QKPQGMQHTHRNNQ-TZCGUCFASA-N FC(F)(F)C1=CC=CC=C1C1=NC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound FC(F)(F)C1=CC=CC=C1C1=NC=CC=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 QKPQGMQHTHRNNQ-TZCGUCFASA-N 0.000 description 1
- NKOUBZYAYYFDJP-KECXSFPFSA-N FC(F)(F)C1=CC=CN=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 Chemical compound FC(F)(F)C1=CC=CN=C1CN[C@@H]1CC[C@@H](NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)CC1 NKOUBZYAYYFDJP-KECXSFPFSA-N 0.000 description 1
- UKWKZCOSIPMMEI-JBLHJTENSA-N FC(F)(F)OC1=CC=CC(C=2C(=CC=CN=2)CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 Chemical compound FC(F)(F)OC1=CC=CC(C=2C(=CC=CN=2)CN[C@@H]2CC[C@H](CC2)NC=2N=C(\C=C/3C(NC(=O)S\3)=O)C=CN=2)=C1 UKWKZCOSIPMMEI-JBLHJTENSA-N 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- FELSZVFXICIMBV-NDTFXOKKSA-N N([C@@H]1CC[C@@H](CC1)NC(C)C=1N=C(C=CC=1)C1=CSC=C1)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@@H]1CC[C@@H](CC1)NC(C)C=1N=C(C=CC=1)C1=CSC=C1)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O FELSZVFXICIMBV-NDTFXOKKSA-N 0.000 description 1
- JGPQRWNELVHXQM-LODLPNETSA-N N([C@@H]1CC[C@@H](CC1)NCC=1C=C(N=C2C=CC=CC2=1)C)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@@H]1CC[C@@H](CC1)NCC=1C=C(N=C2C=CC=CC2=1)C)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O JGPQRWNELVHXQM-LODLPNETSA-N 0.000 description 1
- CBSQLXVVSOWQJF-VWXYPVILSA-N N([C@H]1CC[C@@H](CC1)CNCC1=CC=C(C=C1C=1OC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)CNCC1=CC=C(C=C1C=1OC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O CBSQLXVVSOWQJF-VWXYPVILSA-N 0.000 description 1
- FELSZVFXICIMBV-ATMKEBAWSA-N N([C@H]1CC[C@@H](CC1)NC(C)C=1N=C(C=CC=1)C1=CSC=C1)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NC(C)C=1N=C(C=CC=1)C1=CSC=C1)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O FELSZVFXICIMBV-ATMKEBAWSA-N 0.000 description 1
- ACGPEBIYFNDKHI-CGEUJCPXSA-N N([C@H]1CC[C@@H](CC1)NCC1=C(C2=CC=CC=C2C=C1)Br)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=C(C2=CC=CC=C2C=C1)Br)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O ACGPEBIYFNDKHI-CGEUJCPXSA-N 0.000 description 1
- HKFGNXFBNDSBRI-TWIAMEMFSA-N N([C@H]1CC[C@@H](CC1)NCC1=C2C=CC=CC2=CC=C1OC)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=C2C=CC=CC2=CC=C1OC)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O HKFGNXFBNDSBRI-TWIAMEMFSA-N 0.000 description 1
- QUNNMHSFPKXBSB-BLQFWBLFSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)Br)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)Br)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O QUNNMHSFPKXBSB-BLQFWBLFSA-N 0.000 description 1
- IMPAUPYHNAEEJD-BLQFWBLFSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O IMPAUPYHNAEEJD-BLQFWBLFSA-N 0.000 description 1
- AIQTVRDYJBUJON-LGJUQMQDSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)O)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)O)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O AIQTVRDYJBUJON-LGJUQMQDSA-N 0.000 description 1
- UHOLDDFYARGZKY-OUVFEFDQSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)OC)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC2=CC=C(C=C2C=C1)OC)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O UHOLDDFYARGZKY-OUVFEFDQSA-N 0.000 description 1
- YHIAJVCPLHUQRE-GJHHADOSSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C2=CC=CC=C21)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C2=CC=CC=C21)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O YHIAJVCPLHUQRE-GJHHADOSSA-N 0.000 description 1
- HDNQRZDFHVUZJY-SIHSEAKDSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C1=COC=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C1=COC=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O HDNQRZDFHVUZJY-SIHSEAKDSA-N 0.000 description 1
- SPQJMWDXHXRYFZ-SIHSEAKDSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C1=CSC=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C1=CSC=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O SPQJMWDXHXRYFZ-SIHSEAKDSA-N 0.000 description 1
- WEWKLYXLPQUYJZ-YASBIWDDSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1C=CC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1C=CC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O WEWKLYXLPQUYJZ-YASBIWDDSA-N 0.000 description 1
- ZNVCQVJACFGZNC-SZCGDEIFSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1C=NC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1C=NC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O ZNVCQVJACFGZNC-SZCGDEIFSA-N 0.000 description 1
- HCBDIGIMBQRNDS-KAOCFBPMSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1OC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1OC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O HCBDIGIMBQRNDS-KAOCFBPMSA-N 0.000 description 1
- NSCVIWHNIWGDJQ-KAOCFBPMSA-N N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1SC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=CC=C(C=C1C=1SC=CC=1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O NSCVIWHNIWGDJQ-KAOCFBPMSA-N 0.000 description 1
- QRPLCPVIMGBVLO-INSMAYOISA-N N([C@H]1CC[C@@H](CC1)NCC1=NC2=CC=C(C=C2C=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC1=NC2=CC=C(C=C2C=C1)F)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O QRPLCPVIMGBVLO-INSMAYOISA-N 0.000 description 1
- JGPQRWNELVHXQM-KAOCFBPMSA-N N([C@H]1CC[C@@H](CC1)NCC=1C=C(N=C2C=CC=CC2=1)C)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O Chemical compound N([C@H]1CC[C@@H](CC1)NCC=1C=C(N=C2C=CC=CC2=1)C)C(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O JGPQRWNELVHXQM-KAOCFBPMSA-N 0.000 description 1
- 125000005855 N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 125000005861 N—(C1-C6)alkoxycarbonylaminomethyl group Chemical group 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 101150054691 PIM3 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010017121 Proto-Oncogene Proteins c-pim-1 Proteins 0.000 description 1
- 102000004433 Proto-Oncogene Proteins c-pim-1 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- WHEDIEORQRTDMV-KUXDZRIFSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(NC[C@@H]2CC[C@@H](CNCC=3N=C(C=CC=3)C3=CSC=C3)CC2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(NC[C@@H]2CC[C@@H](CNCC=3N=C(C=CC=3)C3=CSC=C3)CC2)=N1 WHEDIEORQRTDMV-KUXDZRIFSA-N 0.000 description 1
- CMZRLRKORYQIOW-DPVGCAPLSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(NC[C@@H]2CC[C@@H](CNCCC=3C=CC=CC=3)CC2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(NC[C@@H]2CC[C@@H](CNCCC=3C=CC=CC=3)CC2)=N1 CMZRLRKORYQIOW-DPVGCAPLSA-N 0.000 description 1
- FFROJIOFQWVHCN-BPCBUOLASA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@@H](CNCC=3N=C(C=CC=3)C3=CSC=C3)CC2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@@H](CNCC=3N=C(C=CC=3)C3=CSC=C3)CC2)=N1 FFROJIOFQWVHCN-BPCBUOLASA-N 0.000 description 1
- IBQUEROKAQSOPD-VGEFMDSNSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@@H](CNCCC=3C=CC=CC=3)CC2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@@H](CNCCC=3C=CC=CC=3)CC2)=N1 IBQUEROKAQSOPD-VGEFMDSNSA-N 0.000 description 1
- UGRWFVWCFNMLOX-LGJUQMQDSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C2=COC=C2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C2=COC=C2)=N1 UGRWFVWCFNMLOX-LGJUQMQDSA-N 0.000 description 1
- PFRNARPPMMZOIT-ZQBBDTFNSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C=2C=CN=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C=2C=CN=CC=2)=N1 PFRNARPPMMZOIT-ZQBBDTFNSA-N 0.000 description 1
- OICYDGOAANRJTQ-OUVFEFDQSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C=2C=NC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C=2C=NC=CC=2)=N1 OICYDGOAANRJTQ-OUVFEFDQSA-N 0.000 description 1
- NIGHEDAWBBMMED-TZCGUCFASA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C=2OC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=CC=CC=2)C=2OC=CC=2)=N1 NIGHEDAWBBMMED-TZCGUCFASA-N 0.000 description 1
- JROFFLZQKMQKDQ-FKRCZJECSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C2=COC=C2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C2=COC=C2)=N1 JROFFLZQKMQKDQ-FKRCZJECSA-N 0.000 description 1
- VQTWZQBKSGWEDF-FKRCZJECSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C2=CSC=C2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C2=CSC=C2)=N1 VQTWZQBKSGWEDF-FKRCZJECSA-N 0.000 description 1
- ISHSWHYTONASJK-NTSFZXAFSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2NC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2NC=CC=2)=N1 ISHSWHYTONASJK-NTSFZXAFSA-N 0.000 description 1
- MNUYIMLQKIVRMI-LIRYTKDYSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2NN=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2NN=CC=2)=N1 MNUYIMLQKIVRMI-LIRYTKDYSA-N 0.000 description 1
- SKVOBWXIVPFCRY-JKEUBQDTSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2OC3=CC=CC=C3C=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2OC3=CC=CC=C3C=2)=N1 SKVOBWXIVPFCRY-JKEUBQDTSA-N 0.000 description 1
- BTKJZPRXHYUYEX-NTSFZXAFSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2OC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C(=NC=CC=2)C=2OC=CC=2)=N1 BTKJZPRXHYUYEX-NTSFZXAFSA-N 0.000 description 1
- FQGGTIFOJIOPFG-JBLHJTENSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C3=CC=CC=C3C=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C3=CC=CC=C3C=CC=2)=N1 FQGGTIFOJIOPFG-JBLHJTENSA-N 0.000 description 1
- GVUPKOKXPMHYHG-OVJBJWPISA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C3=CC=CN=C3C=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C3=CC=CN=C3C=CC=2)=N1 GVUPKOKXPMHYHG-OVJBJWPISA-N 0.000 description 1
- BFOQSLMMSYZPPN-JBLHJTENSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C=C(C=CC=2)C=2OC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C=C(C=CC=2)C=2OC=CC=2)=N1 BFOQSLMMSYZPPN-JBLHJTENSA-N 0.000 description 1
- RFBWTYHNIFZQMG-JBLHJTENSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C=C(C=CC=2)C=2SC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2C=C(C=CC=2)C=2SC=CC=2)=N1 RFBWTYHNIFZQMG-JBLHJTENSA-N 0.000 description 1
- IYAJLGMQFDLART-INSMAYOISA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C2=COC=C2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C2=COC=C2)=N1 IYAJLGMQFDLART-INSMAYOISA-N 0.000 description 1
- ZHMMLBPPMVQZIO-OSNHZDIXSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C=2C=C3OCOC3=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C=2C=C3OCOC3=CC=2)=N1 ZHMMLBPPMVQZIO-OSNHZDIXSA-N 0.000 description 1
- IQPXKPMDMKHWMT-NGXIWGDTSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C=2OC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C=2OC=CC=2)=N1 IQPXKPMDMKHWMT-NGXIWGDTSA-N 0.000 description 1
- JAHRFTVEBGAZEJ-NGXIWGDTSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C=2SC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C=2SC=CC=2)=N1 JAHRFTVEBGAZEJ-NGXIWGDTSA-N 0.000 description 1
- NDVJUWUJRFZRAR-UUDYJFFGSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCCC=2C=CC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCCC=2C=CC=CC=2)=N1 NDVJUWUJRFZRAR-UUDYJFFGSA-N 0.000 description 1
- HFYPMUXSMAWXES-NOGPAOKLSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCCC=2N=CC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@@H]2CC[C@H](CC2)NCCC=2N=CC=CC=2)=N1 HFYPMUXSMAWXES-NOGPAOKLSA-N 0.000 description 1
- GYCAHBIKRFTGPJ-POKCEJIYSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C2=CSC=C2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@H]2CC[C@H](CC2)NCC=2N=C(C=CC=2)C2=CSC=C2)=N1 GYCAHBIKRFTGPJ-POKCEJIYSA-N 0.000 description 1
- NDVJUWUJRFZRAR-JGSSCENWSA-N S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@H]2CC[C@H](CC2)NCCC=2C=CC=CC=2)=N1 Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=NC(N[C@H]2CC[C@H](CC2)NCCC=2C=CC=CC=2)=N1 NDVJUWUJRFZRAR-JGSSCENWSA-N 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000010097 Unknown Primary Neoplasms Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000005021 aminoalkenyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000005586 carbonic acid group Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000013255 cell cycle cytokinesis Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 125000005852 di-N,N—(C1-C2)alkylamino(C2-C3)alkyl group Chemical group 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 1
- RHBMVXBGYGIDJN-UHFFFAOYSA-N furan-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CO1 RHBMVXBGYGIDJN-UHFFFAOYSA-N 0.000 description 1
- IEKOSPNJXYCZHY-UHFFFAOYSA-N furan-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CO1 IEKOSPNJXYCZHY-UHFFFAOYSA-N 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- RNQQJLYJLDQGGL-UHFFFAOYSA-N isoquinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CN=CC2=C1 RNQQJLYJLDQGGL-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- MRHQBBSKCLIMRH-UHFFFAOYSA-N n-(acetamidomethoxymethyl)acetamide Chemical compound CC(=O)NCOCNC(C)=O MRHQBBSKCLIMRH-UHFFFAOYSA-N 0.000 description 1
- XKURZGMTHHIQOT-YHYXMXQVSA-N n-[4-[(z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]pyrimidin-2-yl]-5-(trifluoromethyl)pyridine-2-carboxamide Chemical compound N1=CC(C(F)(F)F)=CC=C1C(=O)NC1=NC=CC(\C=C/2C(NC(=O)S\2)=O)=N1 XKURZGMTHHIQOT-YHYXMXQVSA-N 0.000 description 1
- SYAKBGLEKZCGCZ-TWGQIWQCSA-N n-[4-[(z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]pyrimidin-2-yl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O SYAKBGLEKZCGCZ-TWGQIWQCSA-N 0.000 description 1
- WYGQBGAGASEESB-ZROIWOOFSA-N n-[4-[(z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]pyrimidin-2-yl]quinoline-2-carboxamide Chemical compound C=1C=C2C=CC=CC2=NC=1C(=O)NC(N=1)=NC=CC=1\C=C1/SC(=O)NC1=O WYGQBGAGASEESB-ZROIWOOFSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- BNEVFKZLYCGDFG-UHFFFAOYSA-N quinoline-5-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=N1 BNEVFKZLYCGDFG-UHFFFAOYSA-N 0.000 description 1
- OVZQVGZERAFSPI-UHFFFAOYSA-N quinoline-8-carbaldehyde Chemical compound C1=CN=C2C(C=O)=CC=CC2=C1 OVZQVGZERAFSPI-UHFFFAOYSA-N 0.000 description 1
- JLZCPFISUMNHDT-UHFFFAOYSA-N quinoline-8-carbonyl chloride Chemical compound C1=CN=C2C(C(=O)Cl)=CC=CC2=C1 JLZCPFISUMNHDT-UHFFFAOYSA-N 0.000 description 1
- HPQRQAOVNXWEEQ-UHFFFAOYSA-N quinoline-8-carboxamide Chemical compound C1=CN=C2C(C(=O)N)=CC=CC2=C1 HPQRQAOVNXWEEQ-UHFFFAOYSA-N 0.000 description 1
- ZTYZEUXZHGOXRT-UHFFFAOYSA-N quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)N)=CC=CC2=C1 ZTYZEUXZHGOXRT-UHFFFAOYSA-N 0.000 description 1
- JUYUYCIJACTHMK-UHFFFAOYSA-N quinoline-8-sulfonyl chloride Chemical compound C1=CN=C2C(S(=O)(=O)Cl)=CC=CC2=C1 JUYUYCIJACTHMK-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- TUUNNJSATKVNGO-UHFFFAOYSA-N tert-butyl n-[4-(methylamino)cyclohexyl]carbamate Chemical compound CNC1CCC(NC(=O)OC(C)(C)C)CC1 TUUNNJSATKVNGO-UHFFFAOYSA-N 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 125000005863 α-amino(C1-C4)alkanoyl group Chemical group 0.000 description 1
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555617P | 2011-11-04 | 2011-11-04 | |
| US201161555617P | 2011-11-04 | ||
| PCT/US2012/061597 WO2013066684A1 (en) | 2011-11-04 | 2012-10-24 | Aminopyrimidine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2629690T3 true ES2629690T3 (es) | 2017-08-14 |
Family
ID=47116510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12780393.0T Active ES2629690T3 (es) | 2011-11-04 | 2012-10-24 | Inhibidores de aminopirimidina quinasa |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8927525B2 (https=) |
| EP (1) | EP2776432B1 (https=) |
| JP (1) | JP6215832B2 (https=) |
| KR (1) | KR101990605B1 (https=) |
| CN (1) | CN104011046B (https=) |
| AU (1) | AU2012332931B2 (https=) |
| BR (1) | BR112014010563B1 (https=) |
| CA (1) | CA2853454C (https=) |
| ES (1) | ES2629690T3 (https=) |
| IL (1) | IL232234A0 (https=) |
| MX (1) | MX347191B (https=) |
| PL (1) | PL2776432T3 (https=) |
| RU (1) | RU2674017C2 (https=) |
| WO (1) | WO2013066684A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2516425T3 (pl) * | 2009-12-23 | 2016-03-31 | Jasco Pharmaceuticals Llc | Inhibitory kinaz aminopirydynowych |
| EP2699569B1 (en) * | 2011-04-22 | 2017-08-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| EP2776432B1 (en) | 2011-11-04 | 2017-03-29 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| RS60244B1 (sr) | 2013-01-15 | 2020-06-30 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| MX384172B (es) * | 2015-08-04 | 2025-03-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de pirazol pirimidina y sus usos. |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| TW201837027A (zh) | 2017-02-01 | 2018-10-16 | 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 | 吡唑衍生物及其用途 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| TW202128664A (zh) | 2019-10-09 | 2021-08-01 | 德商拜耳廠股份有限公司 | 作為除害劑之新穎雜芳基三唑化合物 |
| TW202542149A (zh) * | 2023-12-21 | 2025-11-01 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 化合物及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW245716B (https=) | 1992-12-28 | 1995-04-21 | Takeda Pharm Industry Co | |
| US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| IL113112A (en) * | 1994-03-28 | 2000-06-01 | Nissan Chemical Ind Ltd | Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them |
| AU712802B2 (en) | 1994-10-20 | 1999-11-18 | Nippon Chemiphar Co. Ltd. | Quinoline derivatives |
| RU2007101544A (ru) | 2004-06-17 | 2008-08-10 | Уайт (Us) | Антагонисты рецепторов высвобождающего гонадотропин гормона |
| CA2576765C (en) | 2004-09-03 | 2013-05-28 | Applied Research Systems Ars Holding N.V. | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| AU2005293556A1 (en) | 2004-10-12 | 2006-04-20 | Merck Serono Sa | PI3 Kinase gamma inhibitors for the treatment of anaemia |
| EP1916249A1 (en) | 2006-10-10 | 2008-04-30 | LEK Pharmaceuticals D.D. | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents |
| EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| WO2009097113A2 (en) | 2008-01-28 | 2009-08-06 | New York University | Oxazole and thiazole compounds as b-catenin modulators and uses thereof |
| WO2010056549A1 (en) | 2008-10-29 | 2010-05-20 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
| US20100331315A1 (en) * | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
| PL2516425T3 (pl) * | 2009-12-23 | 2016-03-31 | Jasco Pharmaceuticals Llc | Inhibitory kinaz aminopirydynowych |
| EP2699569B1 (en) * | 2011-04-22 | 2017-08-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| EP2776432B1 (en) | 2011-11-04 | 2017-03-29 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
-
2012
- 2012-10-24 EP EP12780393.0A patent/EP2776432B1/en active Active
- 2012-10-24 KR KR1020147014718A patent/KR101990605B1/ko not_active Expired - Fee Related
- 2012-10-24 RU RU2014122344A patent/RU2674017C2/ru active
- 2012-10-24 PL PL12780393T patent/PL2776432T3/pl unknown
- 2012-10-24 CN CN201280053781.XA patent/CN104011046B/zh not_active Expired - Fee Related
- 2012-10-24 JP JP2014539984A patent/JP6215832B2/ja not_active Expired - Fee Related
- 2012-10-24 WO PCT/US2012/061597 patent/WO2013066684A1/en not_active Ceased
- 2012-10-24 BR BR112014010563-4A patent/BR112014010563B1/pt not_active IP Right Cessation
- 2012-10-24 MX MX2014005052A patent/MX347191B/es active IP Right Grant
- 2012-10-24 AU AU2012332931A patent/AU2012332931B2/en active Active
- 2012-10-24 US US13/659,343 patent/US8927525B2/en active Active
- 2012-10-24 ES ES12780393.0T patent/ES2629690T3/es active Active
- 2012-10-24 CA CA2853454A patent/CA2853454C/en active Active
-
2014
- 2014-04-24 IL IL232234A patent/IL232234A0/en active IP Right Grant
- 2014-12-19 US US14/577,079 patent/US9629840B2/en active Active
-
2016
- 2016-12-09 US US15/374,013 patent/US10336743B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL232234A0 (en) | 2014-06-30 |
| AU2012332931B2 (en) | 2017-08-03 |
| AU2012332931A1 (en) | 2014-06-12 |
| JP2015501782A (ja) | 2015-01-19 |
| EP2776432A1 (en) | 2014-09-17 |
| BR112014010563A2 (pt) | 2017-04-25 |
| MX347191B (es) | 2017-04-19 |
| US20170247367A1 (en) | 2017-08-31 |
| US8927525B2 (en) | 2015-01-06 |
| RU2014122344A (ru) | 2015-12-10 |
| KR20140098105A (ko) | 2014-08-07 |
| US20150202205A1 (en) | 2015-07-23 |
| US20130310342A1 (en) | 2013-11-21 |
| CN104011046A (zh) | 2014-08-27 |
| US10336743B2 (en) | 2019-07-02 |
| MX2014005052A (es) | 2015-03-19 |
| PL2776432T3 (pl) | 2017-10-31 |
| BR112014010563B1 (pt) | 2021-01-12 |
| EP2776432B1 (en) | 2017-03-29 |
| US9629840B2 (en) | 2017-04-25 |
| CA2853454A1 (en) | 2013-05-10 |
| RU2674017C2 (ru) | 2018-12-04 |
| JP6215832B2 (ja) | 2017-10-18 |
| WO2013066684A1 (en) | 2013-05-10 |
| CN104011046B (zh) | 2017-05-03 |
| KR101990605B1 (ko) | 2019-06-18 |
| CA2853454C (en) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2629690T3 (es) | Inhibidores de aminopirimidina quinasa | |
| AU2012245344B2 (en) | Aminopyrimidine kinase inhibitors | |
| ES2555224T3 (es) | Inhibidores de aminopirimidina cinasa | |
| US20230118795A1 (en) | Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof | |
| US9073903B2 (en) | Imidazole-2,4-dione inhibitors of casein kinase 1 | |
| CN120943837A (zh) | 作为酪氨酸激酶抑制剂的杂环化合物 |